Found: 15
Select item for more details and to access through your institution.
G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2020, v. 180, n. 3, p. 635, doi. 10.1007/s10549-020-05575-9
- By:
- Publication type:
- Article
Correction to: Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy.
- Published in:
- Breast Cancer Research & Treatment, 2020, v. 179, n. 1, p. 67, doi. 10.1007/s10549-019-05454-y
- By:
- Publication type:
- Article
Targeting mutant estrogen receptors.
- Published in:
- eLife, 2019, p. 1, doi. 10.7554/eLife.44181
- By:
- Publication type:
- Article
Systematic identification of signaling pathways with potential to confer anticancer drug resistance.
- Published in:
- Science Signaling, 2014, v. 7, n. 357, p. 1, doi. 10.1126/scisignal.aaa1877
- By:
- Publication type:
- Article
Author Correction: Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates.
- Published in:
- NPJ Breast Cancer, 2021, v. 7, n. 1, p. 1, doi. 10.1038/s41523-021-00290-0
- By:
- Publication type:
- Article
Development and Characterization of a Luciferase Labeled, Syngeneic Murine Model of Ovarian Cancer.
- Published in:
- Cancers, 2022, v. 14, n. 17, p. 4219, doi. 10.3390/cancers14174219
- By:
- Publication type:
- Article
Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.
- Published in:
- Science Translational Medicine, 2016, v. 8, n. 369, p. 1, doi. 10.1126/scitranslmed.aae0348
- By:
- Publication type:
- Article
Validation of histone deacetylase 3 as a therapeutic target in castration‐resistant prostate cancer.
- Published in:
- Prostate, 2018, v. 78, n. 4, p. 266, doi. 10.1002/pros.23467
- By:
- Publication type:
- Article
Current and emerging estrogen receptor-targeted therapies for the treatment of breast cancer.
- Published in:
- Essays in Biochemistry, 2021, v. 65, n. 6, p. 985, doi. 10.1042/EBC20200174
- By:
- Publication type:
- Article
Dysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors.
- Published in:
- Nature Communications, 2018, v. 9, n. 1, p. 1, doi. 10.1038/s41467-018-04033-x
- By:
- Publication type:
- Article
The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells.
- Published in:
- Nature Communications, 2017, v. 8, n. 1, p. 1, doi. 10.1038/s41467-017-00910-z
- By:
- Publication type:
- Article
Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cells.
- Published in:
- Nature Communications, 2024, v. 15, n. 1, p. 1, doi. 10.1038/s41467-024-52032-y
- By:
- Publication type:
- Article